Accedi a banche dati online | Convegnodetail
Anteprima di stampa
 
 

Triple Negative Breast Cancer Drug Development Summit

Evvnt Promotion / evvnt
-
28.04.2021 - 29.04.2021  Virtual
Time: 08:00 to 16:00
 
Temi della conferenza
This is the primary industry platform specifically dedicated to providing you insight into the latest developments of safe and efficacious blockbuster therapies to treat triple negative breast cancer.

Breast cancer (BC) is the most common solid tumor in women, with the triple negative subtype associated with poorer overall survival and a higher probability of cancer recurrence.
Professional congress organizer (PCO)
Hanson Wade
Annotazioni
Brochure: https://go.evvnt.com/729098-2?pid=4832

Speakers: Alison L. Hannah, Senior Vice President and Chief Medical Officer, CytomX Therapeutics, Angus Sinclair, VP Immuno-Oncology, IGM Biosciences, and more.
 

Informazioni ed Iscrizioni:

https://go.evvnt.com/729098-1?pid=4832
Mr. Customer Services
 
Categorie
Oncologia
Lingua
Inglese
Quote del Congresso
Conference Only (Drug Developer Pricing): USD 1999.00, Conference Only (Service Provider Pricing): USD 2499.00, Conference Only (Academic Pricing): USD 1799.00
I partecipanti attesi
1000 - 1000
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."

Ärztekammer für WienEuropean Public Health Association (EUPHA)European Health Forum GasteinCentro per la Formazione Permanente e l'Aggiornamento del Personale del Servizio SanitarioSwiss Tropical and Public Health InstitutenewTreeHelix - Forschung & Beratung WienOÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation